.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Teva
UBS
McKinsey
Colorcon
US Army
Queensland Health
Healthtrust
Cantor Fitzgerald
Deloitte

Generated: December 18, 2017

DrugPatentWatch Database Preview

Claims for Patent: 6,046,202

« Back to Dashboard

Claims for Patent: 6,046,202

Title: Use of thiazolidinedione derivatives in the treatment of insulin resistance
Abstract:The present invention provides methods of using thiazolidinedione in the treatment of insulin resistance.
Inventor(s): Antonucci; Tammy (Thousand Oaks, CA), Lockwood; Dean (Ann Arbor, MI), Norris; Rebecca (Kewadin, MI)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:09/168,515
Patent Claims: 1. A method of treating a patient having insulin resistance characterized by hyperinsulinemia and failure to respond to exogenous insulin, the method comprising administering to the patient a therapeutically effective amount of (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl )methoxy]phenyl]methyl]-2,4-thiazolidinedione (Troglitazone).

2. A method of treating a patient having insulin resistance characterized by hyperinsulinemia and failure to respond to exogenous insulin, the method comprising administering to the patient a therapeutically effective amount of 5-[p-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione (Pioglitazone).

3. A method of treating a patient having insulin resistance characterized by hyperinsulinemia and failure to respond to exogenous insulin, the method comprising administering to the patient a therapeutically effective amount of 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione (Rosiglitazone).
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Dow
Colorcon
Moodys
Cipla
Harvard Business School
Argus Health
McKinsey
Cantor Fitzgerald
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot